Overview

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Status:
Not yet recruiting
Trial end date:
2027-08-07
Target enrollment:
Participant gender:
Summary
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Niraparib